Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application
Applied DNA Sciences (NASDAQ:APDN) has received a follow-on order valued at over $500,000 for Linea™ DNA from a global manufacturer of in vitro diagnostics (IVDs). This order, placed under a long-standing supply agreement, is for non-therapeutic DNA used in a cancer diagnostic test. The company plans to deliver the order over four quarterly shipments in calendar 2025.
The accelerated receipt of this annually recurring order, coming less than a year after the previous one, suggests a strong customer commitment to Linea DNA. Applied DNA has been servicing this customer with multiple gram-scale orders for nearly a decade, positioning itself well to meet the growing DNA needs of the diagnostic industry and potentially expand its IVD customer base for increased recurring order-flow.
Applied DNA Sciences (NASDAQ:APDN) ha ricevuto un ordine di follow-up del valore di oltre 500.000 dollari per Linea™ DNA da un produttore globale di diagnostica in vitro (IVD). Questo ordine, effettuato nell'ambito di un accordo di fornitura a lungo termine, riguarda DNA non terapeutico utilizzato in un test diagnostico per il cancro. L'azienda prevede di consegnare l'ordine attraverso quattro spedizioni trimestrali nel 2025.
La ricezione accelerata di questo ordine ricorrente annualmente, avvenuta meno di un anno dopo il precedente, suggerisce un forte impegno da parte del cliente verso Linea DNA. Applied DNA ha servito questo cliente con ordini di diverse dimensioni per quasi un decennio, posizionandosi bene per soddisfare le crescenti esigenze di DNA dell'industria diagnostica e potenzialmente espandere la propria base di clienti IVD per aumentare il flusso di ordini ricorrenti.
Applied DNA Sciences (NASDAQ:APDN) ha recibido un pedido adicional valorado en más de 500,000 dólares para Linea™ DNA de un fabricante global de diagnósticos in vitro (IVD). Este pedido, realizado bajo un acuerdo de suministro a largo plazo, es para ADN no terapéutico utilizado en una prueba diagnóstica de cáncer. La empresa planea entregar el pedido en cuatro envíos trimestrales en el año calendario 2025.
La recepción acelerada de este pedido recurrente anual, que llega menos de un año después del anterior, sugiere un fuerte compromiso del cliente con Linea DNA. Applied DNA ha estado atendiendo a este cliente con múltiples pedidos a granel durante casi una década, posicionándose bien para satisfacer las crecientes necesidades de ADN de la industria de diagnóstico y potencialmente expandir su base de clientes IVD para aumentar el flujo de pedidos recurrentes.
Applied DNA Sciences (NASDAQ:APDN)은 50만 달러 이상의 가치가 있는 후속 주문을 받았다고 발표했다. 이 주문은 글로벌 인 비트로 진단 (IVD) 제조업체로부터 Linea™ DNA에 대한 것이다. 이 주문은 암 진단 테스트에 사용되는 비치료 DNA에 해당하는 것으로, 2025년 캘린더 연도에 걸쳐 4회의 분기별 배송으로 전달할 계획이다.
1년이 채 안 되는 기간에 이 연간 반복 주문을 조기에 수령한 것은 Linea DNA에 대한 고객의 강한 의지를 나타낸다. Applied DNA는 거의 10년 동안 이 고객을 위해 여러 그램 규모의 주문을 처리해 왔으며, 진단 산업의 증가하는 DNA 요구 사항을 충족시키기 위해 잘 위치해 있다고 하고 있으며, 잠재적으로 IVD 고객 기반을 확장하여 반복 주문 흐름을 늘릴 수 있다고 보고 있다.
Applied DNA Sciences (NASDAQ:APDN) a reçu une commande supplémentaire d'une valeur de plus de 500 000 dollars pour Linea™ DNA d'un fabricant mondial de diagnostics in vitro (IVD). Cette commande, passée dans le cadre d'un accord de fourniture de longue date, concerne de l'ADN non thérapeutique utilisé dans un test de diagnostic du cancer. L'entreprise prévoit de livrer la commande par le biais de quatre expéditions trimestrielles en 2025.
La réception accélérée de cette commande annuelle récurrente, peu de temps après la précédente, suggère un fort engagement du client envers Linea DNA. Applied DNA fournit ce client avec de nombreuses commandes à l'échelle de grammes depuis près d'une décennie, se positionnant bien pour satisfaire les besoins croissants en ADN de l'industrie diagnostique et potentiellement élargir sa base de clients IVD pour augmenter le flux d'ordres récurrents.
Applied DNA Sciences (NASDAQ:APDN) hat eine Folgeauftrag im Wert von über 500.000 US-Dollar erhalten für Linea™ DNA von einem globalen Hersteller von In-vitro-Diagnostika (IVDs). Dieser Auftrag, der im Rahmen eines langjährigen Liefervertrags erteilt wurde, betrifft nicht-therapeutisches DNA, das in einem Krebsdiagnosetests verwendet wird. Das Unternehmen plant, den Auftrag über vier vierteljährliche Lieferungen im Kalenderjahr 2025 auszuliefern.
Der beschleunigte Erhalt dieses jährlich wiederkehrenden Auftrags, der weniger als ein Jahr nach dem vorherigen erfolgt, deutet auf ein starkes Engagement des Kunden für Linea DNA hin. Applied DNA bedient diesen Kunden seit fast einem Jahrzehnt mit mehreren Großbestellungen und positioniert sich gut, um den wachsenden DNA-Bedarf der Diagnostikindustrie zu decken und möglicherweise seine IVD-Kundenbasis für einen erhöhten wiederkehrenden Auftragfluss auszubauen.
- Received a follow-on order valued at over $500,000 for Linea DNA
- Order placed under a long-standing supply agreement, indicating customer loyalty
- Accelerated receipt of the annual order, suggesting increased demand
- Potential for expanding IVD customer base and increasing recurring order-flow
- None.
The
The multi-year relationship with this global IVD manufacturer demonstrates Applied DNA's ability to retain key customers in the competitive biotech space. The planned delivery over four quarterly shipments in 2025 provides visibility into future revenues, which is important for investor confidence. However, it's important to note that while this order is encouraging, diversifying the customer base remains vital for long-term stability and growth.
The recurring order for Linea™ DNA indicates a sustained demand for cancer diagnostic tests using Applied DNA's technology. This suggests the underlying diagnostic test has gained traction in the medical community, potentially due to its efficacy or cost-effectiveness. The accelerated order timing could imply either improved test performance leading to increased adoption or expanded applications of the diagnostic.
As cancer diagnostics continue to evolve towards more personalized and precise methods, Applied DNA's position in supplying critical components for these tests could lead to further growth opportunities. However, it's important to monitor advancements in competing technologies, such as liquid biopsies or AI-driven diagnostics, which could impact the long-term demand for PCR-based tests.
- Recurring and Accelerated Receipt of Order Reflects Customer Commitment to Linea DNA -
STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced it has received a follow-on order valued at more than
Dr. James A. Hayward, president and CEO of Applied DNA, stated, "We are very encouraged by the receipt of this annually recurring order that now comes less than one year from the customer's prior order. Having serviced this customer with multiple gram-scale orders over nearly a decade, we believe we are well positioned to meet the diagnostic industry's growing need for DNA and expand our IVD customer base for greater recurring order-flow."
About Linea™ DNA
Linea™ DNA is an enzymatically produced, linear DNA manufactured by the Company's proprietary, large-scale polymerase chain reaction ("PCR") based manufacturing platform, the Linea™ DNA platform. As an alternative to plasmid-based DNA, Linea DNA can be used in the manufacture of a wide range of nucleic acid-based therapies and in vitro diagnostics, including mRNA therapies, DNA vaccines, cell and gene therapies, as well as molecular and genetic diagnostic tests.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, the unknown future demand for its biotherapeutics and/or diagnostic products and services, the unknown amount of revenues and profits that will result from its Linea IVT and or Linea DNA platforms, the fact that there has never been a commercial drug product utilizing PCR-produced DNA technology and/or the Linea IVT platform approved for therapeutic use, and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K, as amended, filed on December 7, 2023 and Quarterly Report on Form 10-Q filed on February 8, 2024, May 10, 2024, and August 8, 2024 and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
Contacts:
Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Program contact: Brian Viscount, 631-240-8877, brian.viscount@adnas.com
Web: www.adnas.com
X: @APDN
SOURCE: Applied DNA Sciences
View the original press release on accesswire.com
FAQ
What is the value of the follow-on order received by Applied DNA Sciences (APDN)?
When will Applied DNA Sciences (APDN) deliver the Linea DNA order?
What is the purpose of the Linea DNA ordered from Applied DNA Sciences (APDN)?
How long has Applied DNA Sciences (APDN) been supplying Linea DNA to this customer?
